Navigation Links
Poniard Pharmaceuticals Announces $6.3 Million Financing
Date:3/15/2010

SOUTH SAN FRANCISCO, Calif., March 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the sale of 4,229,000 of its common shares to Commerce Court Small Cap Value Fund, Ltd. for gross proceeds of approximately $6.3 million, or approximately $1.49 per share, under its existing committed equity financing facility with Commerce Court.  Poniard intends to use the approximately $6.1 million in net proceeds from this offering to fund the company's regulatory and partnering strategies focused on the continued development of picoplatin in small cell lung cancer and other indications. Based on its existing cash and investment securities, together with the net proceeds from this offering, Poniard believes it has adequate resources to fund operations at least through the end of 2010.

The securities described above were sold by Poniard Pharmaceuticals pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. For additional information please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements describing the Company's anticipated use of proceeds from the financing, its clinical and regulatory goals and partnering strategy with respect to picoplatin and the adequacy of its current cash resources. Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the results and timing of the Company's on-going process with the FDA; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to retain key personnel and enter into strategic partnerships on favorable terms, or at all; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of any FDA and other required regulatory approvals, if any; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Report on Form 10-Q for the period ended September 30, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

SOURCE Poniard Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.poniard.com

'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
2. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
3. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
4. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
5. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
6. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
7. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
8. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
9. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
10. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
11. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017   Pulmatrix, Inc . (NASDAQ: ... to address serious pulmonary diseases, today announced that it has ... cystic fibrosis and asthma to its Scientific Advisory Board ... Richard B. Moss , MD, former chief of ... the Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 On ... the NASDAQ Composite closed the trading session up 0.19%; ... the S&P 500 was down 0.08%. US markets made ... finishing the day in green. Pre-market today, Stock-Callers.com reviews ... Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx ...
(Date:3/27/2017)... March 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today ... Paul M. Bisaro as Impax,s President and Chief ... effective March 27, 2017. Mr. Bisaro will succeed ... President and Chief Executive Officer since December of 2016. ... branded pharmaceutical experience, Mr. Bisaro, 56, is an accomplished ...
Breaking Medicine Technology:
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... restoration treatment, is proud to announce a new blog post about women’s hair loss. ... women suffer from hair loss as they age. Menopause or genetics can be two ...
(Date:3/28/2017)... Louis, MO (PRWEB) , ... March 28, 2017 ... ... levels of job satisfaction in their profession as their value increases in the ... company that provides resources such as job boards, career fairs, and candidate leads ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to experience the benefits ... now have them placed by Dr. Manju Kejriwal, with or without a referral. Dr. ... increase the accuracy of each dental implant placement. The i-CAT CBCT system captures the ...
(Date:3/27/2017)... ... March 27, 2017 , ... This ... OSEHRA popHealth Community in 2014. It is the culmination of collaborative ... Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded the ONC certification ...
Breaking Medicine News(10 mins):